Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis

  title={Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis},
  author={S.N. Reinke and D Broadhurst and BD Sykes and G. B. Baker and Ingrid Catz and KG Warren and Christopher Power},
  journal={Multiple Sclerosis Journal},
  pages={1396 - 1400}
Metabolomics enables the provision of sensitive bio-markers of disease. We performed 800 MHz 1H-nuclear magnetic resonance (NMR) spectroscopic analyses of cerebrospinal fluid (CSF) specimens to identify biomarkers of multiple sclerosis (MS), yielding reproducible detection of 15 metabolites from MS (n=15) and non-MS (n=17) patients. Mean levels of choline, myo-inositol and threonate were increased, whereas 3-hydroxybutyrate, citrate, phenylalanine, 2-hydroxyisovalerate and mannose were… 

Figures and Tables from this paper

Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis.
H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis
NMR metabolomic analysis was able to discriminate different metabolic profiles in patients with MS compared with HC, and Metabolomics appears to represent a promising noninvasive approach for the study of MS.
Application of metabolomics in autoimmune diseases: Insight into biomarkers and pathology
An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview
The metabolomics studies suggest that metabolic profiling of MS patient samples may uncover biomarkers that will advance the understanding of disease pathogenesis and progression, reduce delays and mistakes in diagnosis, monitor the course of disease, and detect better drug targets, all of which will improve early therapeutic interventions and improve evaluation of response to these treatments.
Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment
Evidence is offered in support of the potential of metabolomics as a biomarker and drug discovery tool in MS and pathway analysis of metabolites described as potential biomarkers in the literature of MS biofluids are used to identify the most promising molecules and upstream regulators.
NMR-based metabolomics of human cerebrospinal fluid identifies signature of brain death.
This study identifies a metabolic signature associated with BD and the most relevant enriched selected metabolic pathways as 1H-NMR spectroscopy in human CSF.
A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica.
Metabolites altered in urine from MS patients were shown to be related to known pathogenic processes relevant to MS, including alterations in energy and fatty acid metabolism, mitochondrial activity, and the gut microbiota.
Metabolomics in multiple sclerosis
Metabolomics has the potential to provide putative biomarkers, insights into the pathophysiology of the disease, and to aid in precision medicine for patients with MS.
Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review
Several promising candidate biomarkers suitable for clinical application in MS have been studied and it is recommended follow-up studies with larger sample sizes be completed on several potential biomarkers.


Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update
Improved metabolomic and other analytical techniques have led to a 54% increase in the known size of the human CSF metabolome over the past 5 years and commonly available metabolomic methods, when combined, can now routinely identify and quantify 36% of the 'detectable' human CSf metabolome.
Inflammatory Multiple-Sclerosis Plaques Generate Characteristic Metabolic Profiles in Cerebrospinal Fluid
CSF metabolic profiles suggest a close link between MS plaque activity in CIS patients on the one hand and organic-acid metabolism on the other, and increased BHIB levels points to a hitherto unsuspected role for this compound in MS with active plaques.
Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy.
In vitro high resolution proton MRS of the CSF constitutes a new and original way to explore CSF for the differential and/or early diagnosis of dementias, as a complement to in vivo proton cerebral MRS.
Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy.
An introduction to metabolites, metabolomes, metabolomics and the role of MS and NMR spectroscopy will be provided and the applications of metabolomics in mammalian systems biology for the study of the health-disease continuum, drug efficacy and toxicity and dietary effects on mammalian health will be reviewed.
Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis.
The unidentified compound is volatile and, from the chemical shift of the observed NMR peak, is probably an N-methyl compound, which may be an intermediate in the cholinoglycine cycle, in which an abnormality has been proposed to exist in MS patients.
1H magnetic resonance spectroscopy in multiple sclerosis and related disorders.
NMR‐based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases – a diagnostic tool?
We sought to evaluate the diagnostic accuracy of metabolomic biomarker profiles in neurological conditions (idiopathic intracranial hypertension (IIH), multiple sclerosis (MS) and cerebrovascular
Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis
There is a concomitant reduction in both lactate and glutamine in the cerebrospinal fluid of patients with multiple sclerosis compared to controls, which may be related to altered astrocytic metabolism during the disease.
The role of mitochondria in axonal degeneration and tissue repair in MS
This topical review will discuss putative pathological mechanisms leading to mitochondrial dysfunction and recent imaging studies performed in vivo in patients with MS, and briefly review therapeutic strategies aimed at improving mitochondrial metabolism and function under neuroinflammatory conditions.
Multiple sclerosis.
The aim of treatment is to reduce the frequency, and limit the lasting effects, of relapses, relieve symptoms, prevent disability arising from disease progression, and promote tissue repair.